Insights

More Articles Back to Article

3 FDA panel members resign after Alzheimer's drug approval

Three members of the FDA's Peripheral and Central Nervous System Advisory Committee have resigned following the agency's decision to approve Biogen's Alzheimer's disease drug Aduhelm despite the panel's nearly unanimous recommendation in November not to recommend approval of the drug. Aaron Kesselheim, a professor of medicine at Harvard Medical School, Washington University neurologist Joel Perlmutter and Mayo Clinic neurologist David Knopman resigned from the advisory panel as a result of the approval. CNBC (6/11)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!